On the morning of April 14, 2026, the signing ceremony of the strategic cooperation agreement between Chengdu High-tech Medical Association and DYIP Investment (Bio) was successfully held. This cooperation marks an important step for the society in expanding its international cooperation efforts and serves as a significant milestone in deepening the integration of medicine and engineering.

Representatives from the Australian Consulate-General in Chengdu, the Australian Trade and Investment Commission, Trade and Investment Queensland, and AustCham Southwest China, along with leaders from the Chengdu High-tech Medical Association and other Chinese and Australian guests, jointly attended the ceremony.

In his speech, Feng Huaizhi, Director of the Med-Engineering Integration Collaborative Innovation Center of Chengdu High-tech Medical Association, pointed out that this cooperation represents not only a virtuous cycle of 'bringing in' and 'going global', but also a new paradigm of international collaboration in 'industry-academia-research-application'. The association will leverage DYIP (Bio)'s advantages in overseas R&D, technological reserves, and international market networks to facilitate the introduction of Australia's advanced achievements in biomedicine, precision medicine, and innovative medical devices into China, serving the grassroots and benefiting patients, while also helping China's original technologies and products reach the global market.

Ye Chenzi, Chairperson of DYIP Investment (Bio), stated that with the support of the Australian Trade and Investment Commission, the Queensland Government, and AustCham Southwest China over the years, DYIP (Bio) has grown into a platform-oriented company with international integration capabilities. In the future, relying on the association, the company will promote deep connections between high-quality biotechnology resources from Queensland and the rest of Australia and Southwest China.

Martin Ferreyra, Deputy Consul-General (Commerce) at the Australian Consulate-General in Chengdu and Commercial Investment Adviser at the Australian Trade and Investment Commission, emphasized that Australia is a global leader in medical health innovation. This cooperation represents a vivid example of Sino-Australian collaborative development in the health industry. The Australian side will continue to provide policy and resource support for bilateral cooperation.

This signing not only establishes a bridge for the bidirectional transformation of biomedical achievements between China and Australia but also injects new momentum into Chengdu's high-level opening-up in the biomedical field. In the future, the two parties will carry out substantive cooperation in areas such as technology introduction, talent exchange, achievement transformation, and joint standard development, jointly writing a new chapter in Sino-Australian biomedical collaboration.